Related Experiment Videos
111In-labeled Mn-metalloporphyrin for tumor imaging
S Nakajima1, H Yamauchi, I Sakata
1Division of Surgical Operation, Asahikawa Medical College, Japan.
Nuclear Medicine and Biology
|February 1, 1993
Summary
A novel tumor imaging agent, 111In-labeled metalloporphyrin (111In-ATN-10), offers clearer tumor delineation than 67Ga-citrate. This agent shows potential as a new positive scintigraphic agent without causing photosensitivity.
Area of Science:
- Radiochemistry
- Oncology
- Medical Imaging
Background:
- Current tumor imaging agents like 67Ga-citrate have limitations.
- Development of novel, more effective tumor-specific imaging agents is crucial.
Purpose of the Study:
- To synthesize and evaluate a new radiolabeled metalloporphyrin, 111In-ATN-10, as a tumor imaging agent.
- To compare the efficacy of 111In-ATN-10 with 67Ga-citrate for tumor visualization.
- To assess the safety profile, specifically photosensitivity, of the new agent.
Main Methods:
- Synthesis of 111In-labeled metalloporphyrin (111In-ATN-10) using ATN-10 carrier with a manganese complex and DTPA chelator.
- In vivo imaging studies in tumor-bearing models.
- Comparative analysis of image quality and tumor delineation between 111In-ATN-10 and 67Ga-citrate.
Main Results:
- 111In-ATN-10 successfully delineated three types of tumors with greater clarity compared to 67Ga-citrate.
- The carrier molecule ATN-10 did not induce photosensitivity.
- The agent demonstrated potential as a positive scintigraphic agent.
Conclusions:
- 111In-ATN-10 is a promising new radiopharmaceutical for tumor imaging.
- It offers improved diagnostic accuracy over 67Ga-citrate.
- The absence of photosensitivity enhances its clinical applicability.